Imaging of αvβ3 expression by a bifunctional chimeric RGD peptide not cross-reacting with α vβ5

Clinical Cancer Research

Volumn 15, Issue 16, 2009, Pages 5224-5233

  Zannetti, Antonella ^a   Del Vecchio, Silvana ^a   Iommelli, Francesca ^a   Del Gatto, Annarita ^a   De Luca, Stefania ^a   Zaccaro, Laura ^a   Papaccioli, Angela ^a   Sommella, Jvana ^a   Panico, Mariarosaria ^a   Speranza, Antonio ^a   Grieco, Paolo ^a   Novellino, Ettore ^a   Saviano, Michele ^a   Pedone, Carlo ^a   Salvatore, Marco ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHAVBETA5 INTEGRIN; ARGINYLGLYCYLASPARTIC ACID; CHIMERIC PROTEIN; ECHISTATIN; FLUORINE 18; INDIUM 111; IODINE 125; PENTAPEPTIDE; PENTETIC ACID; VITRONECTIN RECEPTOR;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING ASSAY; CARBOXY TERMINAL SEQUENCE; CELL ADHESION; CELL MEMBRANE; CONJUGATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; ISOTOPE LABELING; MALE; MOLECULAR WEIGHT; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FUNCTION; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TUMOR XENOGRAFT;

AMINO ACID SEQUENCE; ANIMALS; GLIOBLASTOMA; HUMANS; INTEGRIN ALPHAVBETA3; IODINE RADIOISOTOPES; K562 CELLS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; OLIGOPEPTIDES; PEPTIDES; POSITRON-EMISSION TOMOGRAPHY; PROTEIN BINDING; RECEPTORS, VITRONECTIN; RECOMBINANT FUSION PROTEINS; SUBSTRATE SPECIFICITY; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 69349090351     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-3270     Document Type: Article

References (46)

1. Avraamides CJ, Garmy-Susini B, Varner JA. Integrins in angiogenesis and lymphangiogenesis. Nat Rev Cancer 2008;8:604-617
2. Hood JD, Cheresh DA. Role of integrins in cell invasion and migration. Nat Rev Cancer 2002;2: 91-100. (Pubitemid 37328796)
3. Guo W, Giancotti FG. Integrin signalling during tumour progression. Nat Rev Mol Cell Biol 2004; 5:816-826
4. Stupack DG, Cheresh DA. Get a ligand, get a life: integrins, signaling and cell survival. J Cell Sci 2002;115:3729-3738
5. Friedlander M, Brooks PC, Shaffer RW, Kincaid CM, Varner JA, Cheresh DA. Definition of two angiogenic pathways by distinct αv integrins. Science 1995;270:1500-1502 (Pubitemid 3005294)
6. Hood JD, Frausto R, Kiosses WB, Schwartz MA, Cheresh DA. Differential αv integrin-mediated Ras-ERK signaling during two pathways of angiogenesis. J Cell Biol 2003;162:933-943 (Pubitemid 37087732)
7. Shimaoka M, Springer TA. Therapeutic antagonists and conformational regulation of integrin function. Nat Rev Drug Discov 2003;2: 703-716 (Pubitemid 37361786)
8. Xiong JP, Stehle T, Diefenbach B, et al. Crystal structure of the extracellular segment of integrin αVβ3. Science 2001;294:339-345 (Pubitemid 32963395)
9. Xiong JP, Stehle T, Zhang R, et al. Crystal structure of the extracellular segment of integrin αVβ3 in complex with an Arg-Gly-Asp ligand. Science 2002;296:151-155 (Pubitemid 34280076)
10. Mahabeleshwar GH, Feng W, Reddy K, Plow EF, Byzova TV. Mechanisms of integrin-vascular endothelial growth factor receptor cross-activation in angiogenesis. Circ Res 2007;101:570-580 (Pubitemid 351325874)
11. Byzova TV, Goldman CK, Pampori N, et al. A mechanism for modulation of cellular responses to VEGF: activation of the integrins. Mol Cell 2000;6:851-860
12. Albelda SM, Mette SA, Elder DE, et al. Integrin distribution in malignant melanoma: association of the β3 subunit with tumor progression. Cancer Res 1990;50:6757-6764
13. Schnell O, Krebs B, Wagner E, et al. Expression of integrin αvβ3 in gliomas correlates with tumor grade and is not restricted to tumor vasculature. Brain Pathol 2008;18:378-386 (Pubitemid 351782847)
14. Liapis H, Adler LM, Wick MR, Rader JS. Expression of α(v)β3 integrin is less frequent in ovarian epithelial tumors of low malignant potential in contrast to ovarian carcinomas. Hum Pathol 1997;28:443-449
15. Gasparini G, Brooks PC, Biganzoli E, et al. Vascular integrin α(v)β3: a new prognostic indicator in breast cancer. Clin Cancer Res 1998; 4:2625-2634
16. Felding-Habermann B, O'Toole TE, Smith JW, et al. Integrin activation controls metastasis in human breast cancer. Proc Natl Acad Sci U S A 2001;98:1853-1858 (Pubitemid 32165587)
17. Rolli M, Fransvea E, Pilch J, Saven A, Felding-Habermann B. Activated integrin αvβ3 cooperates with metalloproteinase MMP-9 in regulating migration of metastatic breast cancer cells. Proc Natl Acad Sci U S A 2003;100:9482-9487 (Pubitemid 37033954)
18. Carriero MV, Del Vecchio S, Capozzoli M, et al. Urokinase receptor interacts with α(v)β5 vitronectin receptor, promoting urokinase-dependent cell migration in breast cancer. Cancer Res 1999; 59:5307-5314
19. Monnier Y, Farmer P, Bieler G, et al. CYR61 and αVβ5 integrin cooperate to promote invasion and metastasis of tumors growing in preirradiated stroma. Cancer Res 2008;68:7323-7331
20. Chen X, Conti PS, Moats RA. In vivo near-infrared fluorescence imaging of integrin αvβ3 in brain tumor xenografts. Cancer Res 2004;64: 8009-8014
21. Sipkins DA, Cheresh DA, Kazemi MR, Nevin LM, Bednarski MD, Li KC. Detection of tumor angiogenesis in vivo by αVβ3-targeted magnetic resonance imaging. Nat Med 1998;4:623-626 (Pubitemid 28237365)
22. Zhang C, Jugold M, Woenne EC, et al. Specific targeting of tumor angiogenesis by RGD-conjugated ultrasmall superparamagnetic iron oxide particles using a clinical 1.5-T magnetic resonance scanner. Cancer Res 2007;67:1555-1562 (Pubitemid 46383379)
23. Ellegala DB, Leong-Poi H, Carpenter JE, et al. Imaging tumor angiogenesis with contrast ultrasound and microbubbles targeted to α(v)β3. Circulation 2003;108:336-341
24. Janssen ML, Oyen WJ, Dijkgraaf I, et al. Tumor targeting with radiolabeled α(v)β(3) integrin binding peptides in a nude mouse model. Cancer Res 2002;62:6146-6151
25. Haubner R, Wester HJ, Weber WA, et al. Non-invasive imaging of α(v)β3 integrin expression using 18F-labeled RGD-containing glycopeptide and positron emission tomography. Cancer Res 2001;61:1781-1785
26. Chen X, Hou Y, Tohme M, et al. Pegylated Arg-Gly-Asp peptide: 64Cu labeling and PET imaging of brain tumor αvβ3-integrin expression. J Nucl Med 2004;45:1776-1783
27. Cai W, Wu Y, Chen K, Cao Q, Tice DA, Chen X. In vitro and in vivo characterization of 64Cu-labeled Abegrin, a humanized monoclonal antibody against integrin αvβ3. Cancer Res 2006;66:9673-9681
28. Haubner R, Weber WA, Beer AJ, et al. Non-invasive visualization of the activated αvβ3 integr in in cancer patients by positron emission tomography and [18F]galacto-RGD. PLoS Med 2005;2:e70. (Pubitemid 40629471)
29. Beer AJ, Grosu AL, Carlsen J, et al. [18F]galacto-RGD positron emission tomography for imagingof αvβ3 expression on the neovasculature in patients with squamous cell carcinoma of the head and neck. Clin Cancer Res 2007;13:6610-6616 (Pubitemid 350206795)
30. Del Gatto A, Zaccaro L, Grieco P, et al. Novel and selective α(v)β3 receptor peptide antagonist: design, synthesis, and biological behavior. J Med Chem 2006;49:3416-3420
31. De Luca S, Morelli G. Synthesis and characterization of a sulfated and a non-sulfated cyclic CCK8 analogue functionalized with a chelating group for metal labelling. J Pept Sci 2004;10:265-273 (Pubitemid 38594187)
32. Lang L, Eckelman WC. One-step synthesis of 18F labeled [18F]-N-succinimidyl 4-(fluoromethyl)benzoate for protein labeling. Appl Radiat Isot 1994;45:1155-1163
33. Blystone SD, Lindberg FP, LaFlamme SE, Brown EJ. Integrin β3 cytoplasmic tail is necessary and sufficient for regulation of α5β1 phagocytosis by αvβ3 and integrin-associated protein. J Cell Biol 1995;130:745-754
34. Zannetti A, Iommelli F, Fonti R, et al. Gefitinib induction of in vivo detectable signals by Bcl-2/Bcl-xL modulation of inositol trisphosphate receptor type 3. Clin Cancer Res 2008;14:5209-5219
35. Del Vecchio S, Stoppelli MP, Carriero MV, et al. Human urokinase receptor concentration in malignant and benign breast tumors by in vitro quantitative autoradiography: comparison with urokinase levels. Cancer Res 1993; 53:3198-3206 (Pubitemid 23210335)
36. Thibault G. Sodium dodecyl sulfate-stable complexes of echistatin and RGD-dependent integrins: a novel approach to study integrins. Mol Pharmacol 2000;58:1137-1145 (Pubitemid 30800806)
37. McQuade P, KnIght LC. Radiopharmaceuticals for targeting the angiogenesis marker α(v)β(3). Q J Nucl Med 2003;47:209-220
38. Beer AJ, Schwaiger M. Imaging of integrin αvβ3 expression. Cancer Metastasis Rev 2008; 27:631-644
39. Wu Y, Zhang X, Xiong Z, et al. microPET imaging of glioma integrin {α}v{β}3 expression using (64)Cu-labeled tetrameric RGD peptide. J Nucl Med 2005;46:1707-1718
40. Goodman SL, Holzemann G, Sulyok GA, Kessler H. Nanomolar small molecule inhibitors for αv(β) 6, αv(β)5, and αv(β)3 integrins. J Med Chem 2002; 45:1045-1051
41. Li ZB, Chen K, Chen X. (68)Ga-labeled multimeric RGD peptides for microPET imaging of integrin α(v)β(3) expression. Eur J Nucl Med Mol Imaging 2008;35:1100-1108
42. Nabors LB, Mikkelsen T, Rosenfeld SS, et al. Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma. J Clin Oncol 2007;25:1651-1657 (Pubitemid 46797943)
43. Mizejewski GJ. Role of integrins in cancer: survey of expression patterns. Proc Soc Exp Biol Med 1999;222:124-138 (Pubitemid 29514126)
44. Wakayama M, Abei M, Kawashima R, et al. E1A, E1B double-restricted adenovirus with RGD-fiber modification exhibits enhanced oncolysis for CAR-deficient biliary cancers. Clin Cancer Res 2007;13:3043-3050
45. Pasqualini R, Bodorova J, Ye S, Hemler ME. A study of the structure, function and distribution of β5 integrins using novel anti-β5 monoclonal antibodies. J Cell Sci 1993;105 (Pt 1):101-111 (Pubitemid 23187550)
46. Burvenich IJ, Schoonooghe S, Blanckaert P, et al. Biodistribution and planar γ camera imaging of (123)I- and (131)I-labeled F(ab')(2) and Fab fragments of monoclonal antibody 14C5 in nude mice bearing an A549 lung tumor. Nucl Med Biol 2007;34:257-265